FDA Rejects Hearing for Stomach Paralysis Drug Tradipitant
Published Date: 3/31/2026
Notice
Summary
The FDA has decided not to approve Vanda Pharmaceuticals’ new drug, TRADIPITANT capsules, meant to treat symptoms of gastroparesis. Vanda asked for a hearing to challenge this, but the FDA denied it. This means patients and doctors will have to wait longer for this treatment, and Vanda faces delays and extra costs as they figure out their next move.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
NDA Found Not Approvable as Submitted
On September 18, 2024, the FDA's Office of Immunology and Inflammation issued a complete response letter (CRL) stating that NDA 218489 for TRADIPITANT capsules (85 mg) "could not be approved in its present form." The CRL described specific deficiencies and, where possible, recommended ways Vanda Pharmaceuticals might remedy those deficiencies.
FDA Decision on Hearing Posted to Docket
The FDA issued a decision regarding Vanda's request for a hearing on CDER's proposal to refuse approval of NDA 218489 and submitted that decision to the public docket (Docket No. FDA-2024-N-5933) on March 26, 2026. The decision and related documents are available at Regulations.gov or the Dockets Management Staff in Rockville, MD.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-06186 — Combined Notice of Filings
The Federal Energy Regulatory Commission got new filings about natural gas pipeline rates and company name changes. These updates could affect pipeline customers and companies, with some changes starting as soon as April 1, 2026. If you want to speak up or protest, you need to act by early April deadlines.
Next: 2026-06188 — Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Black Lung Clinics Program Performance Measures, OMB No. 0915-0292-Revision
HRSA is updating how Black Lung Clinics report their yearly progress to make things clearer and easier for them. This affects clinics helping coal miners with lung disease, and HRSA wants your thoughts before finalizing the changes. Comments are due by June 1, 2026, and the update aims to keep the program effective without adding extra hassle or cost.